Mitigating the Itch-Scratch Cycle in Prurigo Nodularis: The Promise of Emerging Therapies

Overview

Provider Statement

This continuing education activity is provided by

Support Statement

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Activity Description

Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by pruritic, hyperkeratotic nodules typically distributed on the trunk and extremities. Dual elements of immune dysregulation and neural amplification perpetuate the itch-scratch cycle. Having a profound negative impact on sleep and quality of life in affected patients, PN is often associated with depression and anxiety. Conventional treatment options for PN are nonspecific and include topical agents, immunomodulatory agents, as well as phototherapy. Treatment options with improved efficacy and good tolerability are needed to improve patient outcomes. Novel therapies that target key inflammatory mediators are emerging, leading to a shift in the treatment landscape. In this interactive program, faculty experts discuss the pathophysiology of PN and disease burden, limitations of current treatment, and the promise of emerging therapies designed to disrupt the itch-scratch cycle and improve patient quality of life.

Target Audience

The intended audience for the activity is dermatologists, dermatology nurses, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with PN.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Describe the immune and neural dysregulation that contributes toward the pathogenesis of PN.
• Differentiate conventional therapies that are used to treat PN, based on their mechanisms of action, efficacy, and safety.
• Explore the use of emerging monoclonal antibodies and small molecules as treatments that may lessen the burden and improve outcomes in patients with PN.
• Recognize the need for a comprehensive, multimodal treatment plan for PN that can improve its overall management.

Activity Chair

Gil Yosipovitch, MD
Professor of Dermatology
Stiefel Chair of Medical Dermatology
Director, Miami Itch Center
Dr Phillip Frost Department of Dermatology and Cutaneous Surgery
Miller School of Medicine
University of Miami
Miami, FL

Faculty

Sarina B. Elmariah, MD, PhD, MPH, FAAD
Associate Professor
University of California San Francisco
San Francisco, CA

Brian S. Kim, MD, MTR
Sol and Clara Kest Professor
Vice Chair of Research
Site Chair, Mount Sinai West and Morningside
Director, Mark Lebwohl Center for Neuroinflammation and Sensation
The Kimberly and Eric J. Waldman Department of Dermatology
Precision Immunology Institute
Friedman Brain Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Planners/Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Barbara A. Niedz, PhD, RN, CPHQ

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 1.0 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release, November 30, 2022, to November 29, 2023.

How to Participate in This Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour Certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant financial relationship(s)

Sarina B. Elmariah, MD, PhD, MPH, FAAD
Advisor: Bellus Health, Galderma, Sanofi-Regeneron, Trevi Therapeutics
Speaker Contracted by Ineligible Company: Incyte, Regeneron, Sanofi-Genzyme

Brian S. Kim, MD, MTR
Consultant: AbbVie, Almirall, Amagma, AstraZeneca, Bristol Myers Squibb, Cara Therapeutics, Clexio Biosciences, CymaBay, Evommune, Galderma, GlaxoSmithKline, Escient, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, Shaperon, Third Harmonic Bio, Trevi Therapeutics
Independent Research Contractor: Cara Therapeutics, LEO Pharma

Gil Yosipovitch, MD
Advisor: Galderma, Lilly, Pfizer, Sanofi-Regeneron, Trevi Therapeutics
Consultant: Arcutis, Escient, Galderma, Leo Pharma, Lilly, Novartis, Pfizer, Sanofi-Regeneron, Trevi Therapeutics
Independent Research Contractor: Bellus Health, Leo Pharma, Lilly, Novartis, Pfizer, Sanofi-Regeneron

Planners/Reviewers report the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP; and Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com